Bristol-Myers Squibb Company (BMY): What’s the Story?

Bristol-Myers Squibb Company (BMY) is an interesting player in the Healthcare space, with a focus on Drug Manufacturers – Major. The stock has been active on the tape, currently trading at $60.48, down from yesterday’s close by -0.66%. Given the stock’s recent action, it seemed like a good time to take a closer look at the company’s recent data.

Fundamental Analysis

Bristol-Myers Squibb Company (BMY) currently trades with a market capitalization of $101.21 Billion. That value represents a market adjusting for revenues that have been growing by 3.93 % on a quarterly year/year basis as of the company’s last quarterly report.

You can get a sense of how sustainable that is by a levered free cash flow of $4.22 Billion over the past twelve months. Generally speaking, earnings are expected to fall in coming quarters. Analysts are forecasting earnings of $0.85 on a per share basis this quarter. Perhaps, that suggests something about why 0.36% of the outstanding share supply is held by institutional investors.

Technical Analysis

We’ve taken a serious look at this stock from a fundamental perspective, but the tale of the tape may offer more hints about what lies under the surface. Looking at the stock’s movement on the chart, Bristol-Myers Squibb Company recorded a 52-week high of $70.05. It is now trading 9.57% off that level. The stock is trading $64.77 its 50-day moving average by 4.29%. The stock carved out a 52-week low down at $51.56.

In recent action, Bristol-Myers Squibb Company (BMY) has made a move of -10.95% over the past month, which has come on weak relative transaction volume. Over the trailing year, the stock is underperforming the S&P 500 by 10.65, and it’s gotten there by action that has been less volatile on a day-to-day basis than most other stocks on the exchange. In terms of the mechanics underlying that movement, traders will want to note that the stock is trading on a float of 0.83% with $1.63 Billion sitting short, betting on future declines. That suggests something of the likelihood of a short squeeze in shares of BMY.

Previous articleTaking a Look at the Data Behind Exelixis, Inc. (EXEL)
Next articleChecking the Overall Picture for McDermott International, Inc. (MDR)